Insurers pocketed $50 billion from Medicare (WSJ) | BCBS Wellvolution platform | Fee cut for doctors
Praveen Suthrum
Cofounder, NextServices | Author, The Shift, Scope Forward | GI Mastermind
Medicare Physician Fee Schedule proposes 2.8% cut to docs (Medical Economics)
The Medicare Physician Fee Schedule for 2025 proposes a 2.8% cut in physician payment rates, a move criticized by major medical organizations like the AMA and MGMA.
Trends in Consolidation of Gastroenterology Practices (ScienceDirect)
Estimates suggest that around 10% of all GI practices in America have some association with PE.
The study's findings highlight ColoSense as a reliable alternative to traditional invasive methods, potentially transforming CRC screening practices.
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test (Mainz Biomed)
Clinical trials demonstrated remarkable accuracy, with a 97% sensitivity for CRC and 88% for advanced adenomas.
Critics worry about price gouging and reduced care quality, but market forces discourage these behaviors. While private equity’s role is debated, some argue it spurs innovation and efficiency.
Blue Shield of California adds new programs for gut health, weight loss in Wellvolution platform (Fierce Healthcare)
Blue Shield of California's Wellvolution platform has added four new programs focusing on gut health and weight loss: Ciba Health, Digbi Health, Wondr Health, and an expansion of DarioHealth.
Insurers Pocketed $50 Billion From Medicare for Diseases No Doctor Treated (The Wall Street Journal)
Private insurers involved in the government’s Medicare Advantage program made hundreds of thousands of questionable diagnoses that triggered extra taxpayer-funded payments from 2018 to 2021.
How Cosmo cranked up the cancer-catching AI behind Medtronic’s GI Genius ColonPro (Medical Design & Outsourcing)
The Cosmo Pharmaceuticals division developed the neural networks that allow ColonPro to spot signs of colon cancer that physicians might miss during a colonoscopy. It was the first and only AI system for colonoscopy when it won FDA de novo clearance in 2021.
Although adherence to standardized reporting guidelines ranged from 82.4% to 92.2% in published trials of colorectal cancer screening, researchers found that reporting of trial registration and informed consent materials could be improved.
Morphic's oral IBD drug spurs $3.2B takeout from Lilly (FirstWord PHARMA)
Eli Lilly will pay around $3.2 billion in cash to acquire Morphic, gaining the latter's lead programme for inflammatory bowel disease (IBD).
In this article, Sam Altman and Arianna Huffington discuss the potential of AI to revolutionize healthcare by driving behavior change.
Gastroenterology's special issue delves into new perspectives and innovations in celiac disease research.
Individuals with fair or worse bowel preparation have lower adenoma detection rates and a higher risk for post colonoscopy colorectal cancer (PCCRC) death, new data showed.
State-by-state breakdown of new GI centers in 2024 (Becker’s GI & Endoscopy)
Highlights include Arizona Digestive Health’s new clinic in Tucson, Denver Digestive Health Specialists’ new facility in Colorado, and U.S. Digestive Health’s new center in Pennsylvania.
For weekly gastroenterology business/tech updates directly in your inbox, subscribe to the Scope Forward newsletter .